Ads
related to: prostate cancer drug trials- Dosing & Administration
Learn About Dosing Considerations
For This Targeted Treatment.
- Efficacy Information
Physicians, See How A Targeted
Treatment May Help Your Patients.
- Physician Resources
Download The Patient Brochure &
Other Helpful Resources Here.
- Safety Profile
Physicians, See Safety
Information About This Treatment.
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.
The trial will evaluate the safety and efficacy of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor when dosed in combination with enzalutamide, an androgen receptor inhibitor ...
The candidate, JANX007, reduced prostate-specific (PSA) antigen levels in a majority of the 23 patients who received the drug, the company said late on Monday, adding that deeper reductions were ...
PROSTVAC is being developed in partnership with the National Cancer Institute under a formal Cooperative Research and Development Agreement and has been the subject of multiple ongoing and completed clinical studies, including the global Phase 3 PROSPECT study underway in patients with asymptomatic or minimally symptomatic metastatic prostate cancer (mCRPC). [2]
The FDA approved relugolix based on evidence from a clinical trial (NCT03085095) of 930 participants 48 to 97 years old with advanced prostate cancer. [18] The trial was conducted at 155 sites in the United States, Canada, and countries in South America, Europe and the Asia Pacific region. [ 18 ]
As of August 2014, a clinical trial administering sipuleucel-T in conjunction with ipilimumab (Yervoy) was tracking subjects but no longer enrolling new subjects; the trial evaluates the clinical safety and anti-cancer effects (quantified in PSA, radiographic and T cell response) of the combination therapy in patients with advanced prostate cancer.
Ads
related to: prostate cancer drug trials